Sei Investments Co. Acquires 18,873 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Sei Investments Co. boosted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 7.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 271,387 shares of the medical research company’s stock after acquiring an additional 18,873 shares during the period. Sei Investments Co. owned 0.97% of Bio-Rad Laboratories worth $89,156,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Metis Global Partners LLC increased its position in Bio-Rad Laboratories by 4.4% during the 4th quarter. Metis Global Partners LLC now owns 712 shares of the medical research company’s stock worth $234,000 after buying an additional 30 shares during the period. Signaturefd LLC increased its position in Bio-Rad Laboratories by 13.2% during the 4th quarter. Signaturefd LLC now owns 265 shares of the medical research company’s stock worth $87,000 after buying an additional 31 shares during the period. Avior Wealth Management LLC increased its position in Bio-Rad Laboratories by 3.3% during the 3rd quarter. Avior Wealth Management LLC now owns 999 shares of the medical research company’s stock worth $334,000 after buying an additional 32 shares during the period. UMB Bank n.a. increased its position in Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after buying an additional 32 shares during the period. Finally, Thrivent Financial for Lutherans increased its position in Bio-Rad Laboratories by 0.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company’s stock worth $1,488,000 after buying an additional 32 shares during the period. Institutional investors own 65.24% of the company’s stock.

Wall Street Analysts Forecast Growth

BIO has been the topic of several recent research reports. Wells Fargo & Company lowered their price objective on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Stock Performance

BIO opened at $256.42 on Friday. The firm has a market cap of $7.18 billion, a P/E ratio of -3.94 and a beta of 0.98. Bio-Rad Laboratories, Inc. has a 52-week low of $244.00 and a 52-week high of $387.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The business’s fifty day moving average is $303.23 and its 200-day moving average is $325.28.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.